Latest News and Press Releases

BURLINGTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...

Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the...

BURLINGTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...

Type C Meeting to solidify re-filing plans for FUROSCIX® scheduled with the U.S. Food and Drug Administration (FDA) for June 2019 Resubmission of FURSOCIX New Drug Application (NDA) with the FDA in...

Signed development agreement with West Pharmaceutical Services for next-generation FUROSCIX® On-Body Infusor Resubmission of FURSOCIX with the U.S. Food and Drug Administration (FDA) by year-end 2020...

BURLINGTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...

Advancing FUROSCIX® with the SmartDose® Drug Delivery System Forecast 2018 year-end cash of $82 - $87 million and 2019 expenditures of $8 - $10 million per quarter BURLINGTON, Mass., Jan. 29, 2019 ...

Resubmission of FURSOCIX® with the U.S. Food and Drug Administration (FDA) by year-end 2019 Balance sheet remains strong with over $95 million in cash BURLINGTON, Mass., Nov. 13, 2018 (GLOBE...

Type A Post-Action Meeting Minutes Received BURLINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and...

Request for Type A meeting was granted by the U.S. Food and Drug Administration to discuss the Complete Response Letter received in June 2018 Balance sheet remains strong with over $100 million in...